Somya Dunn
Suggested For You
case study
July 8th, 2026
Operating as an Integrated Regulatory Writing and Submission Partner for Small and Mid-Size Pharmaceutical Companies
perspectives
July 7th, 2026
Don’t Veer for Deer: Why Drug Development Needs Steady Steering in the Age of AI and Real-Time Data.
perspectives
July 6th, 2026
How REMS Defines the Patient Journey in Psychedelic Therapies
perspectives
June 30th, 2026
The Future of Biostatistics: Insights from Presenters at PSI 2026
webinar
June 24th, 2026
The Shift Toward Parallel Submissions in Global Regulatory Strategy
case study
June 30th, 2026
Turning Regulatory Pressure into a Strategic Partnership: Public Release of Clinical Information (PRCI) for a Large Biotech Organization
whitepaper
June 24th, 2026
Psychedelics, FDA Acceleration, and the Coming REMS Reality
perspectives
June 11th, 2026
AI in Regulatory Strategy: Practical Uses for Submission Readiness
news
June 8th, 2026
MMS Highlights Expanded West Coast Biotech Engagement Ahead of BIO International Convention 2026
perspectives
June 3rd, 2026
What Pharma Can Learn from Data Science Outside the Industry
perspectives
May 19th, 2026
Turning Real-World Data into Reliable Evidence: The Role of Data Science
perspectives
May 13th, 2026
Beyond Data Cleaning: A Strategic Shift for Clinical Data Management under ICH E6 (R3)